Press Releases

 
Press Releases
  Date Title and Summary View
Sep 18, 2003
New Brunswick, NJ - Amicus Therapeutics, Inc., an emerging drug development company focused on the development of a novel therapeutic approach to the treatment of human genetic disorders, with an initial focus on lysosomal storage diseases, announced today the issuance of U.S. Patent number 6,599,919. This marks Amicus' fourth U.S. Patent for...
PDF
Mar 8, 2004
New Brunswick, NJ - Amicus Therapeutics, Inc., an emerging drug development company focused on the development of a novel therapeutic approach to the treatment of human genetic disorders, with an initial focus on lysosomal storage diseases, today announced that the U.S. Food & Drug Administration (FDA) has granted Amicus orphan-drug status for...
PDF
May 12, 2004
New Brunswick, NJ - Amicus Therapeutics, Inc., an emerging drug development company focused on the development of a novel therapeutic approach to the treatment of human genetic disorders, with an initial focus on lysosomal storage diseases, today announced the completion of a $31 million Series B private equity financing. The Series B Round was...
PDF
Aug 5, 2004
New Brunswick, NJ - Amicus Therapeutics, Inc., an emerging drug development company focused on the development of a novel therapeutic approach to the treatment of human genetic disorders, with an initial focus on lysosomal storage diseases, today announced that it has initiated a Phase I clinical trial with its first clinical candidate, AT100...
PDF
Jan 24, 2005
North Brunswick, NJ - Amicus Therapeutics, an emerging biopharmaceutical company, today announced the appointment of John F. Crowley as chairman and CEO. Mr. Crowley was most recently founding president and CEO of Orexigen Therapeutics. Prior to this Mr. Crowley was senior vice president of Genzyme Therapeutics and founding president and CEO of ...
PDF
Sep 8, 2005
Cranbury, NJ, September 8, 2005 - Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-active pharmacological chaperones for the treatment of human genetic diseases, today announced the closing of a $55 million Series C financing. The company intends to use the proceeds to advance its drug pipeline based on the co...
PDF
Sep 8, 2005
Cranbury, NJ, September 8, 2005 - Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-active pharmacological chaperones for the treatment of human genetic diseases, today announced positive results from Phase I clinical studies of its lead compound Amigal™ (migalastat hydrochloride) that is being developed ...
PDF
Jan 4, 2006
Cranbury, NJ, January 4, 2006 - Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-active pharmacological chaperones for the treatment of human genetic diseases, today announced that the company will present at the 24th Annual JPMorgan Healthcare Conference. This will be the company's first public presentation ...
PDF
Jan 6, 2006
Cranbury, NJ, January 6, 2006 - Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-active pharmacological chaperones for the treatment of human genetic diseases, today announced that David J. Lockhart, Ph.D. has been appointed chief scientific officer. Dr. Lockhart most recently served as president and chief sc...
PDF
Feb 15, 2006
Cranbury, NJ, February 15, 2006 - Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-active pharmacological chaperones for the treatment of human genetic diseases, today announced that AT2101 has received orphan drug designation from the U.S. Food and Drug Administration. AT2101 is an experimental, oral therapy...
PDF
Page:
1
... NextLast